Menu

  • Log In
  • Contact Us
  • About Us
  • Terms & Policies
  • Privacy Statement
  • Stock Market Mentor
  • Option Market Mentor
  • Crypto Market Mentor
  • Sign up
  • Log in

Option Market Mentor

Menu

  • Trading Videos
    • Fitz in Five
    • Live Training Sessions
  • Trading Room
    • Trading Room
  • Stocks
    • Active Trade List
    • Strategy Sessions
    • Live Training Sessions
  • Options
    • Option Trades List
    • Video Archive
  • Crypto
    • Crypto Video Library
    • Join Crypto Market Mentor
  • Education
    • Tutorial Video Library
    • Options Calculators
    • Options Dictionary
    • Dictionary & Acronyms
    • Options Learning Center
  • Video Archives
  • Store
  • Log in
Skip to content

Menu

  • Trading Videos
    • Fitz in Five
    • Live Training Sessions
  • Trading Room
    • Trading Room
  • Stocks
    • Active Trade List
    • Strategy Sessions
    • Live Training Sessions
  • Options
    • Option Trades List
    • Video Archive
  • Crypto
    • Crypto Video Library
    • Join Crypto Market Mentor
  • Education
    • Tutorial Video Library
    • Options Calculators
    • Options Dictionary
    • Dictionary & Acronyms
    • Options Learning Center
  • Video Archives
  • Store
  • Log in
Skip to content

Tagged: SUPN

Home » Tag: SUPN

Two generic drug makers with good medicine for the bulls. Mylan (MYL) and Supernus Pharmaceutica..

Two generic drug makers with good medicine for the bulls. Mylan (MYL) and Supernus Pharmaceutica..

by DAN Free Chart
November 25, 2013 05:00 PM Tagged: free_chart, MYL, SUPN

© 2024 Option Market Mentor All Rights Reserved. Reproduction without permission prohibited.
Investing involves substantial risk. No guarantee or other promise of performance or as to any results may be obtained from use of this information. The information provided herein is for educational purposes only and are only the ideas of the author with no guarantee of the outcome of such ideas. While past performance and/or references to potential future performance may be referenced or analyzed, past performance should not be considered indicative of future performance and references to potential future performance are only the opinion of the author and should not be relied upon without first conducting your own research and due diligence. No subscriber should make any investment decision without first conducting his or her own research and due diligence, including carefully reviewing the charts related to such security as well as the prospectus and any and all other public filings of the issuer of any security. The information provided is based upon and obtained from sources believed to be reliable. However, none of the information obtained or relied upon has been independently verified or otherwise investigated.